Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.47 |
| ▸ | MEN1 | O00255 | 4/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | NPC1 | O15118 | 4/20 | 0.47 |
| ▸ | CASP3 | P42574 | 1/20 | 0.47 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.47 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.47 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.47 |
| ▸ | MKNK1 | Q9BUB5 | 5/20 | 0.46 |
| ▸ | MKNK2 | Q9HBH9 | 5/20 | 0.46 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.43 |
| ▸ | AXL | P30530 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5159101 | 0.86 | VCP (0.39) | RAB9AMEN1KMT2ANPC1CASP3 | |
| SCHEMBL5001904 | 0.84 | RAB9A (0.48) | RAB9AMEN1KMT2ANPC1CASP3 | |
| SCHEMBL716307 | 0.81 | KDM4E (0.52) | RAB9AMEN1KMT2ANPC1CASP3 | |
| SCHEMBL720660 | 0.77 | NPC1 (0.44) | RAB9AMEN1KMT2ANPC1CASP3 | |
| SCHEMBL718546 | 0.77 | ABL1 (0.49) | KDM4EMAPTTDP1ALDH1A1SMN1; SMN2 | |
| SCHEMBL4834856 | 0.77 | GAA (0.72) | RAB9AMEN1KMT2ANPC1CASP3 | |
| SCHEMBL714837 | 0.77 | NPC1 (0.53) | RAB9AMEN1KMT2ANPC1CASP3 | |
| SCHEMBL5503213 | 0.77 | ABL1 (0.51) | KDM4EMAPTTDP1ALDH1A1SMN1; SMN2 | |
| SCHEMBL6269851 | 0.77 | CYP19A1 (0.49) | RAB9AMEN1KMT2ANPC1CASP3 | |
| SCHEMBL27904707 | 0.76 | RAB9A (0.52) | RAB9AMEN1KMT2ANPC1MKNK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8993573-B2 | 2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors | AB SCIENCE (FR) | 2015-03-31 | — | — | US | disclosed |
| US-8835435-B2 | 2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors | AB SCIENCE (FR) | 2014-09-16 | — | — | US | disclosed |
| US-20140088108-A1 | 2-(3-AMINOARYL) AMINO-4-ARYL-THIAZOLES AND THEIR USE AS C-KIT INHIBITIORS | AB SCIENCE (FR) | 2014-03-27 | — | — | US | disclosed |
| US-8450302-B2 | 2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors | AB SCIENCE (FR) | 2013-05-28 | — | — | US | disclosed |
| US-20080255141-A1 | Modulators of signal transduction mediated by certain native and/or mutant tyrosine kinases; antiproliferative, anticarcinogenic, antiallergen, and antiinflammatory agents; metabolic and neurodegenerative disorders | AB SCIENCE | 2008-10-16 | — | — | US | disclosed |
| US-20070225293-A1 | Use of C-Kit Inhibitors for Treating Fibrosis | AB SCIENCE | 2007-09-27 | — | — | US | disclosed |
| US-20070191267-A1 | Use of tyrosine kinase inhibitors for treating cerebral ischemia | AB SCIENCE | 2007-08-16 | — | — | US | disclosed |
| US-20070032521-A1 | Use of c-kit inhibitors for treating type II diabetes | AB SCIENCE | 2007-02-08 | — | — | US | disclosed |
| EP-1742633-A2 | USE OF C-KIT INHIBITORS FOR TREATING FIBROSIS | AB Science (FR) | 2007-01-17 | — | — | EP | disclosed |
| EP-1653934-A2 | USE OF C-KIT INHIBITORS FOR TREATING TYPE II DIABETES | AB Science (FR) | 2006-05-10 | — | — | EP | disclosed |
| EP-1624873-A2 | USE OF TYROSINE KINASE INHIBITORS FOR TREATING CEREBRAL ISCHEMIA | AB Science (FR) | 2006-02-15 | — | — | EP | disclosed |
| WO-2005102346-A2 | USE OF C-KIT INHIBITORS FOR TREATING FIBROSIS | AB SCIENCE (FR) | 2005-11-03 | — | — | WO | disclosed |
| US-20050239852-A1 | 2-(3-aminoaryl)amino-4-aryl-thiazoles and their use as c-kit inhibitors | AB SCIENCE (FR) | 2005-10-27 | — | — | US | disclosed |
| EP-1525200-A1 | 2-(3-AMINOARYL)AMINO-4-ARYL-THIAZOLES AND THEIR USE AS C-KIT INHIBITORS | AB Science (FR) | 2005-04-27 | — | — | EP | disclosed |
| WO-2005016323-A2 | USE OF C-KIT INHIBITORS FOR TREATING TYPE II DIABETES | AB SCIENCE (FR) | 2005-02-24 | — | — | WO | disclosed |
| WO-2004096225-A2 | USE OF TYROSINE KINASE INHIBITORS FOR TREATING CEREBRAL ISCHEMIA | AB SCIENCE (FR) | 2004-11-11 | — | — | WO | disclosed |
| US-20040110810-A1 | e.g., 2-(2-methyl-5-amino)phenyl-4-(3-pyridyl)-thiazole; c-kit inhibitors; treating cell proliferative, metabolic, allergic, and degenerative disorders. | AB SCIENCE | 2004-06-10 | — | — | US | disclosed |
| WO-2004014903-A1 | 2-(3-AMINOARYL)AMINO-4-ARYL-THIAZOLES AND THEIR USE AS C-KIT INHIBITORS | AB SCIENCE (FR) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225293-A1 | Use of C-Kit Inhibitors for Treating Fibrosis | KIT, CPA3, CMA1 | RAB9A 1274/4885MEN1 2998/4885KMT2A 1338/4885 |
| US-20040110810-A1 | e.g., 2-(2-methyl-5-amino)phenyl-4-(3-pyridyl)-thiazole; c-kit inhibitors; treating cell proliferative, metabolic, allergic, and degenerative disorders. | KIT, MAP3K2, CMA1 | RAB9A 2337/4885MEN1 2693/4885KMT2A 254/4885 |
| US-20070032521-A1 | Use of c-kit inhibitors for treating type II diabetes | KIT, CPA3, CMA1 | RAB9A 1942/4885MEN1 1706/4885KMT2A 359/4885 |
| US-20070191267-A1 | Use of tyrosine kinase inhibitors for treating cerebral ischemia | KIT, MAST3, CPA3 | RAB9A 2244/4885MEN1 2878/4885KMT2A 1679/4885 |
| US-20140088108-A1 | 2-(3-AMINOARYL) AMINO-4-ARYL-THIAZOLES AND THEIR USE AS C-KIT INHIBITIORS | KIT, CHUK, CKS1B | RAB9A 1773/4885MEN1 3413/4885KMT2A 267/4885 |
| US-20050239852-A1 | 2-(3-aminoaryl)amino-4-aryl-thiazoles and their use as c-kit inhibitors | KIT, CHUK, MAP3K2 | RAB9A 1962/4885MEN1 3405/4885KMT2A 361/4885 |
| US-20080255141-A1 | Modulators of signal transduction mediated by certain native and/or mutant tyrosine kinases; antiproliferative, anticarcinogenic, antiallergen, and antiinflammatory agents; metabolic and neurodegenerative disorders | KIT, MAP3K1, MAP3K6 | RAB9A 3051/4885MEN1 3551/4885KMT2A 974/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.